U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Clinical Review Report: Slexipag (Uptravi) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Sep.

Cover of Clinical Review Report: Slexipag (Uptravi)

Clinical Review Report: Slexipag (Uptravi) [Internet].

Show details

References

1.
Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009 Oct;30(20):2493-537. [PubMed: 19713419]
2.
Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D34-D41. [PubMed: 24355639]
3.
Tran K, Coyle K, Jabr MF, Coyle D, Boucher M, Mielniczuk L, et al. Drugs for pulmonary arterial hypertension: comparative efficacy, safety, and cost-effectiveness [Internet]. Ottawa: CADTH; 2015 Mar. (CADTH therapeutic review report). [cited 2015 Aug 19]. Available from: https://www​.cadth.ca​/sites/default/files​/pdf/TR0006_PAH_ScienceReport.pdf [PubMed: 27077175]
4.
Drugs for pulmonary arterial hypertension: comparative efficacy, safety, and cost-effectiveness recommendations report [Internet]. Ottawa: CADTH; 2015. [cited 2016 Jun 1]. (CADTH therapeutic review report). Available from: https://www​.cadth.ca​/sites/default/files​/pdf/TR0006_PAH_Recs_Report.pdf [PubMed: 27077171]
5.
Lajoie AC, Lauziere G, Lega JC, Lacasse Y, Martin S, Simard S, et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med. 2016 Apr;4(4):291-305. [PubMed: 26935844]
6.
Actelion Pharmaceuticals’ response to June 20, 2016 CDR request for additional information regarding Uptravi® (selexipag) CDR review: additional details for CSR study AC-065A302 (GRIPHON) [CONFIDENTIAL additional manufacturer’s information]. Laval, QC: Actelion Pharmaceuticals Canada Inc.; 2016 Jun 30.
7.
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, et al. Selexipag for the treatment of pulmonary arterial hypertension. Supplementary appendix. N Engl J Med. 2015 Dec 24;373(26):2522-33. [PubMed: 26699168]
8.
Clinical Study Report: AC-065A302 (GRIPHON). Prostacylin (PGI2) receptor agonist in pulmonary arterial hypertension: a multicenter, double-blind, placebo-controlled phase 3 study assessing the efficacy and safety of selexipag (ATC-293987) on morbidity and mortality in patients with pulmonary arterial hypertension (PAH). [CONFIDENTIAL internal manufacturer’s report]. Allschwil, Switzerland: Actelion Pharmaceuticals; 2014 Oct 2.
9.
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015 Dec 24;373(26):2522-33. [PubMed: 26699168]
10.
Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006 May 1;173(9):1023-30. [PubMed: 16456139]
11.
Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J [Internet]. 2007 Jul [cited 2015 Aug 25];30(1):104-9. Available from: http://erj​.ersjournals​.com/content/30/1/104.full.pdf+html [PubMed: 17360728]
12.
Frost AE, Badesch DB, Barst RJ, Benza RL, Elliott CG, Farber HW, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US contemporary registries. Chest [Internet]. 2011 Jan [cited 2015 Aug 25];139(1):128-37. Available from: http://journal​.publications​.chestnet.org​/data/Journals/CHEST/20389/100075.pdf [PubMed: 20558556]
13.
Escribano-Subias P, Blanco I, Lopez-Meseguer M, Lopez-Guarch CJ, Roman A, Morales P, et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J. 2012 Sep;40(3):596-603. [PubMed: 22362843]
14.
CDR submission: Adempas© (riociguat) 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg tablets for the treatment of pulmonary arterial hypertension (PAH). Company: Bayer Inc. [CONFIDENTIAL manufacturer’s submission]. Mississauga (ON): Bayer Inc.; 2015 Jun.
15.
Adempas© (riociguat) film-coated tablet, 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg [product monograph]. Mississauga (ON): Bayer Inc.; 2014 Nov 21.
16.
PrOpsumitT (macitentan) 10 mg film-coated tablet [product monograph]. Laval (QC): Actelion Pharmaceuticals Canada Inc.; 2013 Nov 1.
17.
PrVolibris(ambrisentan) 5 mg and 10 mg tablets [product monograph] [Internet]. Mississauga (ON): GlaxoSmithKline Inc.; 2015 Jun 12. [cited 2015 Aug 21]. Available from: http://www​.gsk.ca/english​/docs-pdf/product-monographs​/Volibris.pdf
18.
PrTracleer (bosentan) monohydrate (film coated) tablet. Bosentan 62.5, 125 mg [product monograph]. Allschwil (Switzerland): Actelion Pharmaceuticals Ltd.; 2011 Jun 27.
19.
PrRevatio* (sildenafil) 20 mg tablets, 0.8 mg/mL solution for injection [product monograph]. Kirkland (QC): Pfizer Canada Inc.; 2015 May 5.
20.
PrAdcirca© (tadalafil) 20 mg tablets [product monograph]. Toronto: Eli Lilly Canada Inc.; 2015 Jan 26.
21.
PrFlolan (epoprostenol) powder for injection, 0.5 or 1.5 mg per vial [product monograph]. Mississauga (ON): GlaxoSmithKline Inc.; 2015 Jul 14.
22.
PrRemodulin (treprostinil sodium) injection,1.0, 2.5,5.0 and 10.0 mg/mL of treprostinil [product monograph]. Research Triangle Park (NC): United Therapeutics Corporation; 2008 Sep 25.
23.
PrUptravi (selexipag): 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1000 mcg, 1200 mcg, 1400 mcg, 1600 mcg film-coated tablets; oral [product monograph]. Laval (QC): Actelion Pharmaceuticals Canada, Inc.; 2016 Jan 19.
24.
CDR submission: Uptravi (selexipag), 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1000 mcg, 1200 mcg, 1400 mcg, 1600 mcg film-coated tablets; oral. Actelion Pharmaceuticals Canada, Inc. [CONFIDENTIAL manufacturer’s submission]. Laval (QC): Actelion Pharmaceuticals Canada, Inc.; 2016 Mar 30.
25.
Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Medical review(s). In: Uptravi (selexipag). Company: Actelion Pharmaceuticals, Ltd. Application no.: 207947. Approval date: 12/21/2015 [Internet]. Rockville (MD): FDA; 2015 Mar 2 [cited 2016 Apr 7]. (FDA drug approval package). Available from: http://www​.accessdata​.fda.gov/drugsatfda_docs​/nda/2015/207947Orig1s000MedR.pdf
26.
Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Statistical review(s). In: Uptravi (selexipag). Actelion Pharmaceuticals, Ltd. Application no.: 207947. Approval date: 12/21/2015 [Internet]. Rockville (MD): FDA; 2015 Mar 3 [cited 2016 Apr 7]. (FDA drug approval package). Available from: http://www​.accessdata​.fda.gov/drugsatfda_docs​/nda/2015/207947Orig1s000StatR.pdf
27.
Health Canada reviewer’s report: Uptravi (selexipag) [CONFIDENTIAL internal report]. Ottawa: Therapeutics Products Directorate, Health Canada; 2015 Dec 23.
28.
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, et al. Selexipag for the treatment of pulmonary arterial hypertension. Protocol. N Engl J Med [Internet]. 2015 Dec 24 [cited 2016 Apr 21];373(26):2522-33. Available from: Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015 Dec 24;373(26):2522-33 [PubMed: 26699168]
29.
Actelion Pharmaceuticals Canada Inc. response to June 7 2016 CDR request for additional information regarding the Uptravi® (selexipag) CDR review [CONFIDENTIAL additional manufacturer’s information]. Laval (QB): Actelion Pharmaceuticals Canada Inc.; 2016 Jun 17.
30.
Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013 Aug 29;369(9):809-18. [PubMed: 23984728]
31.
Tomlinson G, Detsky AS. Composite end points in randomized trials: there is no free lunch. JAMA. 2010 Jan 20;303(3):267-8. [PubMed: 20085955]
32.
Cordoba G, Schwartz L, Woloshin S, Bae H, Gotzsche PC. Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review. BMJ. 2010;341:c3920. Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles/PMC2923692 [PMC free article: PMC2923692] [PubMed: 20719825]
33.
Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009 Jun 9;119(22):2894-903. [PubMed: 19470885]
34.
Ventetuolo CE, Benza RL, Peacock AJ, Zamanian RT, Badesch DB, Kawut SM. Surrogate and combined end points in pulmonary arterial hypertension. Proc Am Thorac Soc. 2008 Jul 15;5(5):617-22. [PubMed: 18625754]
35.
Frost AE, Badesch DB, Miller DP, Benza RL, Meltzer LA, McGoon MD. Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis. Chest. 2013 Nov;144(5):1521-9. [PubMed: 23907471]
36.
McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res. 2006 Feb;15(1):103-15. [PubMed: 16411035]
37.
Meads DM, McKenna SP, Doughty N, Das C, Gin-Sing W, Langley J, et al. The responsiveness and validity of the CAMPHOR Utility Index. Eur Respir J [Internet]. 2008 Dec [cited 2016 May 17];32(6):1513-9. Available from: http://erj​.ersjournals​.com/content/erj/32/6/1513.full.pdf [PubMed: 18768576]
38.
Taichman DB, McGoon MD, Harhay MO, Archer-Chicko C, Sager JS, Murugappan M, et al. Wide variation in clinicians’ assessment of New York Heart Association/World Health Organization functional class in patients with pulmonary arterial hypertension. Mayo Clin Proc. 2009 Jul;84(7):586-92. [PMC free article: PMC2704130] [PubMed: 19567712]
39.
Gabler NB, French B, Strom BL, Palevsky HI, Taichman DB, Kawut SM, et al. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation [Internet]. 2012 Jul 17 [cited 2015 Oct 28];126(3):349-56. Available from: http://circ​.ahajournals​.org/content/126/3/349.full.pdf+html [PMC free article: PMC4237273] [PubMed: 22696079]
40.
Fritz JS, Blair C, Oudiz RJ, Dufton C, Olschewski H, Despain D, et al. Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension. Chest. 2013 Feb 1;143(2):315-23. [PMC free article: PMC4694187] [PubMed: 22814814]
41.
Savarese G, Paolillo S, Costanzo P, D’Amore C, Cecere M, Losco T, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol. 2012 Sep 25;60(13):1192-201. [PubMed: 22995024]
42.
Mathai SC, Puhan MA, Lam D, Wise RA. The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. Am J Respir Crit Care Med [Internet]. 2012 Sep 1 [cited 2015 Oct 28];186(5):428-33. Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles​/PMC3443803/pdf/AJRCCM1865428.pdf [PMC free article: PMC3443803] [PubMed: 22723290]
43.
Hassoun PM, Nikkho S, Rosenzweig EB, Moreschi G, Lawrence J, Teeter J, et al. Updating clinical endpoint definitions. Pulm Circ. 2013 Jan;3(1):206-16. Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles/PMC3641732 [PMC free article: PMC3641732] [PubMed: 23662199]
44.
McLaughlin VV, Badesch DB, Delcroix M, Fleming TR, Gaine SP, Galie N, et al. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S97-107. [PubMed: 19555863]
45.
Galie N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D60-D72. [PubMed: 24355643]
46.
Gomberg-Maitland M, Thenappan T, Rizvi K, Chandra S, Meads DM, McKenna SP. United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). J Heart Lung Transplant. 2008 Jan;27(1):124-30. [PubMed: 18187098]
47.
Ganderton L, Jenkins S, McKenna SP, Gain K, Fowler R, Twiss J, et al. Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Australian and New Zealand population. Respirology. 2011 Nov;16(8):1235-40. [PubMed: 21810146]
48.
Twiss J, McKenna S, Ganderton L, Jenkins S, Ben-L’amri M, Gain K, et al. Psychometric performance of the CAMPHOR and SF-36 in pulmonary hypertension. BMC Pulmonary Medicine [Internet]. 2013 [cited 2016 May 17];13(1). Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles​/PMC3751055/pdf/1471-2466-13-45.pdf [PMC free article: PMC3751055] [PubMed: 23844640]
49.
McKenna SP, Ratcliffe J, Meads DM, Brazier JE. Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses. Health and Quality of Life Outcomes [Internet]. 2008 [cited 2016 May 17];6. Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles​/PMC2546377/pdf/1477-7525-6-65.pdf [PMC free article: PMC2546377] [PubMed: 18718016]
50.
American Thoracic Society. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. [PubMed: 12091180]
51.
Hoeper MM, Oudiz RJ, Peacock A, Tapson VF, Haworth SG, Frost AE, et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):48S-55S. [PubMed: 15194178]
52.
Kadikar A, Maurer J, Kesten S. The six-minute walk test: a guide to assessment for lung transplantation. J Heart Lung Transplant. 1997 Mar;16(3):313-9. [PubMed: 9087875]
53.
Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):487-92. [PubMed: 10673190]
54.
Paciocco G, Martinez FJ, Bossone E, Pielsticker E, Gillespie B, Rubenfire M. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J. 2001 Apr;17(4):647-52. [PubMed: 11401059]
55.
Guideline on the clinical investigations of medicinal products for the treatment of pulmonary arterial hypertension [Internet]. London: European Medicine Agency; 2009 Oct 22. [cited 2016 May 20]. Available from: http://www​.ema.europa​.eu/docs/en_GB/document_library​/Scientific_guideline​/2009/12/WC500016686.pdf
56.
Farber HW, Miller DP, McGoon MD, Frost AE, Benton WW, Benza RL. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. J Heart Lung Transplant [Internet]. 2015 Mar [cited 2016 May 20];34(3):362-8. Available from: http://ac​.elscdn.com​/S1053249814012960/1-s2​.0-S1053249814012960-main​.pdf?_tid=743e7290-1eb7-11e6ab36-00000aacb35f&acdnat​=1463768576_82ae281306829a0078044a5cc3764d3a [PubMed: 25312386]
57.
Huang J, Mehta S, Mura M. Early decline in six-minute walk distance from the time of diagnosis predicts clinical worsening in pulmonary arterial hypertension. Respiration. 2015;89(5):365-73. [PubMed: 25791910]
58.
De Feo S, Tramarin R, Lorusso R, Faggiano P. Six-minute walking test after cardiac surgery: instructions for an appropriate use. Eur J Cardiovasc Prev Rehabil. 2009 Apr;16(2):144-9. [PubMed: 19378394]
59.
Guyatt GH, Pugsley SO, Sullivan MJ, Thompson PJ, Berman L, Jones NL, et al. Effect of encouragement on walking test performance. Thorax. 1984 Nov;39(11):818-22. [PMC free article: PMC459930] [PubMed: 6505988]
60.
Rasekaba T, Lee AL, Naughton MT, Williams TJ, Holland AE. The six-minute walk test: a useful metric for the cardiopulmonary patient. Intern Med J. 2009 Aug;39(8):495-501. [PubMed: 19732197]
61.
Oudiz RJ, Barst RJ, Hansen JE, Sun XG, Garofano R, Wu X, et al. Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension. Am J Cardiol. 2006 Jan 1;97(1):123-6. [PubMed: 16377296]
62.
Frost AE, Langleben D, Oudiz R, Hill N, Horn E, McLaughlin V, et al. The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. Vascul Pharmacol. 2005;43(1):36-9. [PubMed: 15890561]
Copyright © 2017 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK533867
Contents

Views

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...